Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
-
J Obstet Gynaecol Can · Dec 2017
Practice GuidelineNo. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
This technical update addendum reviews success rates and comparative evidence of the anticholinergic fesoterodine, as well as mechanism of action, safety profile, success rates, and comparative evidence of the β3 agonist mirabegron in the treatment of non-neurogenic overactive bladder syndrome (OAB). This adds to OAB pharmacotherapy recommendations initially published in 2012. ⋯ Not applicable.